ANI Pharmaceuticals, Inc.
ANIP
$82.10
-$0.57-0.69%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 210.14% | 473.81% | -13.87% | -989.70% | -343.12% |
| Total Depreciation and Amortization | 43.71% | 58.41% | 55.87% | 48.74% | 3.56% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 0.61% | -18.54% | -11.62% | 1,302.87% | 762.91% |
| Change in Net Operating Assets | -314.16% | 904.35% | 113.00% | -117.21% | 49.62% |
| Cash from Operations | 253.17% | 335.35% | 91.53% | -64.55% | -61.22% |
| Capital Expenditure | -26.83% | 9.78% | 45.99% | -5.05% | -176.71% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 90.49% | -- | -- | 96.56% | 77.58% |
| Cash from Investing | 98.45% | -55.29% | -322.17% | -123.50% | -8,652.95% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 99.31% | -170.80% | -170.80% | 79.20% | -39,150.00% |
| Issuance of Common Stock | 721.31% | 23.58% | -2.20% | -13.66% | -78.64% |
| Repurchase of Common Stock | -53.53% | 57.62% | -15.49% | -37.66% | -1.49% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | 15.27% | 0.00% | 0.00% | 0.00% | 0.00% |
| Other Financing Activities | 99.95% | -- | -- | 54.18% | -- |
| Cash from Financing | -97.82% | -20.32% | 49.78% | 58.83% | 7,650.47% |
| Foreign Exchange rate Adjustments | 868.00% | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 147.13% | 490.61% | -33.90% | -100.44% | -403.12% |